Os remédios de emagrecer mais bizarros que as pessoas já usaram

Hormônio tireoidiano para emagrecer, anfetamina para emagrecer, flenfluramina, fenilpropanolamina, sibutramina, rimonabanto, Orlistate, vermes, suar e até quebrar costelas - tudo isso já foi padrão em algum momento da história da humanidade como estratégia de emagrecimento. A gente te conta toda essa história hoje. #históriadamedicina #emagrecimento Seja membro deste canal e apoie a divulgação científica brasileira: https://www.youtube.com/channel/UCdKJlY5eAoSumIlcOcYxIGg/join Roteiro: Ana Bonassa Produção: Ana Bonassa Edição: Laís Maurelli / Jessica Santana Design da miniatura: Laura Marise Legendas: Beatriz Pinheiro Busca de conteúdos: www.nv1c.com Referências - Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med. 2010. doi: 10.1056/NEJMoa1003114. - Effect of sibutramine on weight loss and blood pressure: a meta-analysis of controlled trials. Obes Res. 2003. doi: 10.1038/oby.2003.152. - Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial. Arch Intern Med. 2000. doi: 10.1001/archinte.160.14.2185. - Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med. 2000. doi: 10.1001/archfami.9.2.160. - Past, present and future of pharmacotherapy for obesity. Clin Investig Arterioscler. 2017. English, Spanish. doi: 10.1016/j.arteri.2017.06.002. - Pharmacological therapies for obesity. Gastroenterol Clin North Am. 2005. doi: 10.1016/j.gtc.2004.12.002. - Pharmacological Therapy of Obesity: Past, Present, and Future, The Journal of Clinical Endocrinology & Metabolism, 2003. doi.org/10.1210/jc.2003-030151 - Pharmacological treatment of obesity. Past, present, and future. Minn Med. 2000. PMID: 11126476. - Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med. 2000. doi: 10.1056/NEJM200012213432501.. - Present and future: pharmacologic treatment of obesity. J Obes. 2011. doi: 10.1155/2011/636181. - Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care. 1998. doi: 10.2337/diacare.21.8.1288. - SCOUT Investigators. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med. 2010. doi: 10.1056/NEJMoa1003114. - The current status and future perspectives of studies of cannabinoid receptor 1 antagonists as anti-obesity agents. Curr Top Med Chem. 2009. doi: 10.2174/156802609788897844. - Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 1997. doi: 10.1056/NEJM199708283370901. Erratum in: N Engl J Med 1997. - Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA. 1999. doi: 10.1001/jama.281.3.235. - XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004. doi: 10.2337/diacare.27.1.155. Erratum in: Diabetes Care. 2004. Acompanhe o NV1C nas redes: instagram.com/nuncavi1cientista tiktok.com/@nuncavi1cientista Livro Super-Heróis da Ciência: https://amzn.to/3qZRtxm Apoie este canal! - programa de membros: https://bit.ly/3zwlny9 - chave Pix: [email protected] Quer mandar coisinhas pra gente? Caixa postal: 77785 CEP: 05593-970